by Mears ER, Modabber F, Don R, and Johnson GE. PLoS Neglected Tropical Diseases 9(9): e0003889. doi:10.1371/journal. pntd.0003889, 2015
Summary: The current in vivo models for the utility and discovery of new potential anti-leishmanial drugs targeting cutaneous leishmaniasis differ vastly in their immunological responses to the disease and clinical presentation of symptoms. This review assesses the efficacy and limitations of the various CL models and their potential for drug discovery and evaluation
